Drugs / Hylan G-F 20
Hylan G-F 20
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02368561 | Mar 2015 → Jan 2016 | tendinitis | Meir Medical Center | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03190369 | Aug 2017 → Jan 2019 | osteoarthritis, knee | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00398866 | Aug 2006 → Mar 2013 | osteoarthritis | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT07692009 | Jan 2024 → Jun 2026 | osteoarthritis, knee | Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan S. | Completed | No outcome recorded |
| Phase 4 | NCT01810809 | Apr 2013 → Jun 2014 | osteoarthritis, hip | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01586338 | Mar 2012 → Sep 2013 | osteoarthritis | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01874574 | Jan 2011 → Jun 2013 | osteoarthritis, knee | Thammasat University | Completed | No outcome recorded |
| Phase 4 | NCT02389452 | Feb 2010 → Sep 2011 | osteoarthritis | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT00393393 | Jan 2006 | osteoarthritis | Cabrini Medical Centre | Unknown | No outcome recorded |
| Phase 4 | NCT02197026 | Oct 1998 → Feb 2000 | osteoarthritis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT01132677 | May 2010 → May 2011 | osteoarthritis, knee | LifeMark Health | Unknown | No outcome recorded |
| — | NCT00971074 | Dec 2009 → Dec 2011 | arthropathy | Grant Jones | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 8 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02674399 Comparator | Feb 2016 → Mar 2018 | osteoarthritis, knee | Nature Cell Co. Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02694146 Comparator | Mar 2016 → May 2018 | osteoarthritis, hip | Fundación Pública Andaluza Progreso y Salud | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT05492851 Comparator | Aug 2022 → Jan 2023 | osteoarthritis, knee | Ohio State University | Terminated | No outcome recorded |
| Phase 4 | NCT03694821 Comparator | Jul 2018 → Jul 2019 | osteoarthritis | UConn Health | Terminated | No outcome recorded |
| Phase 4 | NCT03484091 Comparator | Apr 2018 → Jun 2023 | osteoarthritis, knee | Thammasat University | Completed | No outcome recorded |
| Phase 4 | NCT03090698 Comparator | Sep 2015 → Apr 2017 | osteoarthritis, knee | Fluminense Federal University | Unknown | No outcome recorded |
| Phase 4 | NCT01335321 Comparator | Mar → Nov 2011 | osteoarthritis | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02108496 Comparator | Jul 2014 → Jun 2021 | osteoarthritis | Active Implants | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hylan G-F 20 | “Generic Name: Hylan G-F 20 Synvisc-One combines the three doses of SYNVISC (hylan G-F 20) which consists of hylan A (average molecular weight6,000,000 daltons) and hylan B...” NCT05492851 ↗17“Infiltrations of 2 mL 0.8% Hylan G-F 20 (16 mg) solution, administered by intraarticular injections” NCT07692009 ↗ “patients who receive a single injection of Hylan G-F 20 (Synvisc One™) for treatment of knee OA.” NCT01132677 ↗ “Hylan G-F 20 (GZ402662/SAR402662)” NCT03190369 ↗ “GZ402662; hylan G-F 20” NCT02389452 ↗ |
| Known as | GZ402662 | “Hylan G-F 20 (GZ402662/SAR402662)” NCT03190369 ↗ |
| Known as | Hyaluronic acid crosslinked | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297767 ↗ |
| Known as | SAR402662 | “Hylan G-F 20 (GZ402662/SAR402662)” NCT03190369 ↗ |
| Known as | Synvisc | “Generic Name: Hylan G-F 20 Synvisc-One combines the three doses of SYNVISC (hylan G-F 20) which consists of hylan A (average molecular weight6,000,000 daltons) and hylan B...” NCT05492851 ↗4“Two courses of Hylan G-F 20 ( Synvisc) administered by intra-articular injection at 6 monthly intervals.” NCT00393393 ↗ “Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.” NCT02108496 ↗ “A intraarticular injection of 6ml of Hylan GF-20 (Synvisc)” NCT01335321 ↗ “Injection of Hyaluronic Acid -" SYNVISC" (hylan G-F 20)” NCT02368561 ↗ |
| Known as | Synvisc One | “Generic Name: Hylan G-F 20 Synvisc-One combines the three doses of SYNVISC (hylan G-F 20) which consists of hylan A (average molecular weight6,000,000 daltons) and hylan B...” NCT05492851 ↗2“patients who receive a single injection of Hylan G-F 20 (Synvisc One™) for treatment of knee OA.” NCT01132677 ↗ |
| Modality | Other / unclassified | “48 mg of cross-linked hylan polymer” NCT02389452 ↗ |
| Route | Other | “Patients allocated to the HA group will receive a single IA injection Hylan G-F 20 Synvisc One™ (1 injection of 6cc's).” NCT01132677 ↗ |